Tag Archive | "HPV-16"
OralDNA Labs introduces OraRisk HPV salivary diagnostic test
Source: www.rdhmag.com Author: press release OralDNA Labs , a leader in advancing wellness in dentistry through salivary diagnostics and a subsidiary of Quest Diagnostics, recently introduced a OraRisk HPV test. The test is a noninvasive, screening tool to identify the type(s) of oral human papillomavirus (also called HPV). Oral HPV is a mucosal viral infection that is a [...]
Continue reading...New vaccine against HPV approved in Canada
Thursday, February 11, 2010
Source: www.ctv.ca Author: staff Canadian women have a choice of two vaccines against HPV, the family of viruses that can cause cervical cancer, now that Health Canada has approved GlaxoSmithKline’s vaccine, Cervarix. The vaccine, which is expected to be available by the end of the month, will compete against Gardasil, a product of Merck Canada, which has been [...]
Continue reading...HPV-associated base of tongue squamous cell carcinoma incidence increasing in Sweden
Friday, February 5, 2010
Source: www.hemonctoday.com Author: staff The incidence for base of tongue squamous cell carcinoma increased significantly in Sweden between 1998 and 2007, and by 2007, more than 80% of these cases were HPV-positive. Various studies during the past 20 years have indicated that HPV is a risk factor for oropharyngeal cancer. However, few studies have assessed the specific sub-sites [...]
Continue reading...Liverpool scientists working on vaccine for mouth cancer
Monday, January 4, 2010
Source: www.liverpoolecho.co.uk Author: Liza Williams ONE central project the scientists and doctors are working on is a vaccine for mouth cancer. Liverpool researchers have found some cases are caused by the HPV virus – the same bug which causes cervical cancer. They have discovered that two-thirds of tonsil cancer tumour samples showed evidence of the HPV-16 [...]
Continue reading...Vaccines plus screening could end cervical cancer
Wednesday, December 30, 2009
Source: www.cancernetwork.com Author: Fram Lowry Out with the old and in with the new is a commonly followed maxim in medicine given the rapid pace of developments in diagnosis and treatment. Human papillomavirus vaccines are relative newcomers to the cervical cancer armamentarium, but they cannot be relied on to do the job on their own; screening is [...]
Continue reading...Cervarix® vaccination against HPV lasts at least six years
Monday, December 7, 2009
Source: professional.cancerconsultants.com Author: staff Researchers affiliated with the GlaxoSmithKline Vaccine HPV-007 Study Group have reported that Cervarix® [human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine] has “high and sustained immunogenicity, and a favorable safety” profile for up to 6.4 years following administration. The details of this study appeared in an early online publication in the Lancet on December 3, 2009.[1] Cervarix [...]
Continue reading...HPV vaccine clears viral infection and may reduce cancerous lesions
Tuesday, November 10, 2009
Source: www.newswise.com Author: staff Breakthrough study reports complete and partial remissions following vaccination A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine. According to a report published in the November 5 [...]
Continue reading...Human papillomavirus infection and cancers of the oropharynx
Tuesday, October 13, 2009
Source: www.ajho.com Author: Robert Haddad, MD Dana Farber Cancer Institute, Boston, MA The author was invited to contribute his thoughts on the topic of human papillomavirus and cancers of the oropharynx. Squamous cell carcinoma of the head and neck (SCCHN) is a major public health problem, affecting nearly half a million individuals worldwide each year. These cancers can arise [...]
Continue reading...DNA test could be key to targeting treatments for head and neck cancer
Tuesday, October 13, 2009
Source: news.biocompare.com Author: staff It is estimated that more than 7,000 people are diagnosed with head and neck cancer each year in the UK and approximately 3,500 cases result in death. These cancers include tumours of the mouth, lips, throat and voice-box, and some have been linked to the sexually transmitted infection, HPV-16. Scientists at Liverpool analysed [...]
Continue reading...Scientists identify common HPV genotypes In Northern India, encourage vaccination
Tuesday, October 13, 2009
Source: www.sciencedaily.com Author: press release Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region, according to data presented at the American Association for Cancer Research Frontiers in [...]
Continue reading...- Samuel Broder: Why Isn't There a Gardasil for Men?
- Snus news & other tobacco products
- High dosage brachytherapy obtains excellent results in head and neck tumors
- A vaccine debate once focused on sex shifts as boys join the target market
- Consistent evidence to support the use of xylitol- and sorbitol-containing chewing gum to prevent dental caries
- Bill would bar sales of dissolvable tobacco
- R. J. Reynolds introducing 'dissolvable' tobacco
- Smoking debate has become nicotine-delivery debate
- Israeli study sees link between oral cancer, cell phones
- Periodontitis associated with fourfold increased risk for squamous cell carcinoma of the head and neck
- hilllaguna: Negating that nicotine replacement therapies are p...
- OC Advocate: It comes a little surprise that this "test" which ...
- hilllaguna: By world medical treatment standards a diagnosis t...
- Oral Cancer Foundation News Team: After sending this retrospective look to major can...
- hilllaguna: The mathematical probably that you have been expos...
- Office-Based Ultrasound-Guided FNA Found To Be Superior In Diagnosing Head And Neck Lesions
- Why men’s health is a feminist issue
- BT Pharma secures EUR 13.1million (USD 17.7 million) in capital funding and changes its name to Genticel
- Cancer survivor tells his experience with smokeless tobacco
- Mayo oral cancer study shows full tumor genome
- Viagra, Cialis do more than arouse
- Avoid incense
- Transoral robotic surgery showed good oncologic, functional outcomes
- Prolonged treatment delay did not affect outcomes in SCCHN
- Instant screening device is the best defense for detecting deadly oral cancer
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Tuesday, March 2, 2010
0 Comments